Enhancing Uniformity in Advanced Therapy Medicinal Product (ATMP) Manufacturing: Cryopreservation Boosts Europe's Cell Therapy Supply Network Strength

Enhancing Uniformity in Advanced Therapy Medicinal Product (ATMP) Manufacturing: Cryopreservation Boosts Europe's Cell Therapy Supply Network Strength

In a significant step forward for the cell therapy industry, Cryoport Systems has announced the launch of its IntegriCell cryopreservation service in Europe. This service, now available at a dedicated centre in Villers-le-Bouillet, Belgium, is set to revolutionise the way cell and gene therapies (CGTs) are stored and transported across the continent.

The IntegriCell service is designed to maintain the viability, stability, and consistency of cellular products, which are crucial for the efficacy of advanced therapy medicinal products (ATMPs). By integrating IntegriCell into its expansive supply chain platform, Cryoport aims to streamline upstream workflows, reduce supply chain complexity, and ensure the integrity of leukapheresis-derived cellular materials through temperature-controlled preservation.

This move is part of a larger industry focus on supporting CGTs with robust and adaptable supply chain solutions. The localised cryopreservation centre in Europe ensures high standards of temperature control, biostorage, and compliance, addressing the logistical challenges that arise as the demand for cell therapies increases.

The availability of cryopreservation capabilities within Europe prioritises cell quality and regulatory compliance in the CGT community. Access to regional cryopreservation services bolsters logistical efficiency for European CGT developers, while the expansion of IntegriCell services into Belgium reflects a commitment to meeting the immediate logistical needs of the ATMP field.

Cryoport's IntegriCell service complements its broader European network, which includes logistics hubs in the Netherlands and the UK, and biostorage and BioServices centres in France. This infrastructure enables efficient temperature-controlled transport, chain of compliance, and scalable delivery of biologic products, helping developers manage complex multi-jurisdictional logistics while protecting sensitive cellular materials from collection through manufacturing to final administration.

In essence, Cryoport's IntegriCell service in Europe bolsters the cell and gene therapy supply chain by providing specialised cryopreservation capabilities to maintain cell product quality and viability within a coordinated, compliant, end-to-end cold chain network designed specifically for ATMPs. Cryopreservation solutions are key to localising Europe's cell therapy supply chain, ensuring that cell therapies are more reliably available to patients, no matter their location.

1. Cryoport's IntegriCell service in Europe, designed for cell and gene therapies (CGTs), is set to transform the storage and transportation of these crucial medical-conditions treatments.
2. By integrating IntegriCell into its supply chain platform, Cryoport aims to support advanced therapy medicinal products (ATMPs) with streamlined workflows, reducing supply chain complexity, and ensuring leukapheresis-derived cellular materials' integrity.
3. The localised cryopreservation centre in Europe promotes health-and-wellness by addressing logistical challenges, maintaining high standards of temperature control, biostorage, and compliance.
4. As part of its broader European network, Cryoport's IntegriCell service enhances the cell and gene therapy industry by providing specialised cryopreservation solutions, thereby localising Europe's cell therapy supply chain, ensuring better accessibility for patients across the continent.

Read also: